News & Press

  • New Chairman and extended board at Isofol Medical AB (publ)

    Regulatory press release

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling...

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical...

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    Non regulatory press release

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/))...

  • Isofol announces that an abstract with new research resultshas been published for this year's ASCO congress in Chicago

    Regulatory press release

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's annual...

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    Regulatory press release

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States...

  • Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels...

  • Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    Regulatory press release

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult...

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name...

  • Isofol reports successful outcome from the scientific advice with the EMA

    Regulatory press release

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines...

  • Isofol’s CEO, directors and employees converts stock - and employee options and subscribe shares for SEK 7 655 136

    Non regulatory press release

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated...

  • Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Regulatory press release

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology...

  • Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Regulatory press release

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal...

  • Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin)...

  • Isofol to present at the 10th Annual Biotech Showcase Conference

    Non regulatory press release

  • Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer...

  • ­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Regulatory press release

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience...

  • Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Regulatory press release

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin®...

  • Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation...

  • From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin®...

  • Isofols appoints Sven Erickson as Chief Commercial Officer

    Non regulatory press release

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the...

  • Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal...

  • Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented...

  • Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

    Non regulatory press release

  • Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001...

  • New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Regulatory press release

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented...

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated...

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue...

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American...

  • Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

  • Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Non regulatory press release

  • Isofol’s largest shareholder and co-founder acquires shares in the company

    Non regulatory press release

  • Isofol’s Chairman of the Board acquires shares in the company

    Non regulatory press release

  • Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

    Regulatory press release

  • Invitation: Isofol will present it's contemplated IPO in Stockholm on March 29

    Non regulatory press release

  • Invitation: Isofol will present it's contemplated IPO in Göteborg on March 22

    Non regulatory press release

  • Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

    Regulatory press release

  • Isofol announces its intention to list on Nasdaq First North Premier

    Non regulatory press release

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED...

  • ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION

    Regulatory press release

  • FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®

    Regulatory press release

    Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational...

  • ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING

    Regulatory press release

    Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting...

  • ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.

    Regulatory press release

    Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with...

  • ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®

    Regulatory press release

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs...